| 摘要: |
| ［摘要］ 索拉非尼是多靶点激酶抑制剂，通过抗增殖和抗血管形成作用抑制肿瘤细胞生长和血管形成，其作用机制是靶向抑制丝裂原活化蛋白激酶（Ras/Raf/MAPK）、血管内皮生长因子/血管内皮生长因子受体（VEGF/VEGFR）和核因子κB（NF-κB）等信号传导通路，而这些信号通路在放射时被激活，在肿瘤发生发展过程中起着重要的作用。研究显示，索拉非尼联合放射治疗原发性肝癌有协同效应，但联合方案的基础和临床研究有待进一步探索。 |
| 关键词: 索拉非尼 放射疗法 肝细胞癌 |
| DOI：10.3969/j.issn.1674-3806.2012.09.31 |
| 分类号:R 735.7 |
| 基金项目:广西柳州市科学研究与技术开发计划项目（编号：2008031425） |
|
| Research progress on sorafenib combined with radiation in treatment of hepatocellular carcinoma |
|
ZHENG Qing-ping, LI Jing
|
|
Department of Radiation Oncology, the People′s Hospital of Liuzhou, Guangxi 545001, China
|
| Abstract: |
| ［Abstract］ Sorafenib is a multikinase inhibitor that acts by inhibiting tumor growth and disrupting tumor microvasculature through antiproliferative and anti-angiogenic effects. It exerts these effects via inhibition of multiple targets including Ras/Raf/MAPK, VEGF/VEGFR and NF-κB signal pathways, which can be induced by radiation. Sorafenib combined with radiation in hepatocellular carcinoma treatment has been explored and shown synergistic results. The basic and clinical studies on the effects and mechanisms of the combining modality should be further investigated. |
| Key words: Sorafenib Radiation Hepatocellular carcinoma |
